Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pumosetrag Hydrochloride is an orally available 5-HT3 partial agonist. It is developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.
Description | Pumosetrag Hydrochloride is an orally available 5-HT3 partial agonist. It is developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. |
In vivo | Pumosetrag modulates gastrointestinal activity by delaying liquid gastric emptying through proximal stomach relaxation and enhancing fasting antroduodenal migrating motor complex activity, while also speeding up small intestinal transit. Its effectiveness varies across different sections of the mouse intestine, displaying minimal to no activity. This compound demonstrates regional and species-specific responses, with reduced efficacy compared to 5-HT in the rat's jejunum, ileum, and distal colon, yet showing comparable efficacy and potency in the rat's proximal colon. In contrast, Pumosetrag is more potent and effective than 5-HT across all regions of the guinea pig intestine. Its mechanism, mediated by 5-HT(3) receptors, is confirmed by the inhibitory effect of ondansetron on its actions in rat and guinea pig tissues. |
Alias | MKC-733, DDP-733 |
Molecular Weight | 339.84 |
Formula | C15H18ClN3O2S |
Cas No. | 194093-42-0 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 30 mg/mL (88.28 mM), Sonication and heating are recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.